Floatz logo

31 assets in Skin Cancer

Therapeutic assets addressing Skin Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Prednisone
Skin Cancer
Dana-Farber Cancer InstituteP4BBB (73)
Cyclophosphamide
Skin Cancer
Institute of Oncology LjubljanaP2BB (69)
Sirolimus
Skin Cancer
Dana-Farber Cancer InstituteP4BB (67)
Nivolumab
Skin Cancer
7 Hills Pharma, LLCP3BB (66)
Cis-Diamminedichloroplatinum Ii
Skin Cancer
Toray Industries, IncP3BB (65)
Pembrolizumab
Skin Cancer
Institute of Oncology LjubljanaP2B (62)
Everolimus
Skin Cancer
Dana-Farber Cancer InstituteP4B (61)
Ipilimumab
Skin Cancer
7 Hills Pharma, LLCP2B (60)
Anti-Pd-L1 Monoclonal Antibody Ck-301
Skin Cancer
Dana-Farber Cancer InstituteP4CCC (54)
Atezolizumab
Skin Cancer
British Columbia Cancer AgencyP2CCC (53)
Infliximab
Skin Cancer
Massachusetts General HospitalP2CCC (53)
Gsk-2636771
Skin Cancer
M.D. Anderson Cancer CenterP1/2CCC (48)
Alintegimod
Skin Cancer
7 Hills Pharma, LLCP1/2CC (45)
Mdna11
Skin Cancer
Medicenna Therapeutics, Inc.P1/2CC (45)
Adriamycin
Skin Cancer
Toray Industries, IncP1CC (43)
Carboplatin
Skin Cancer
Toray Industries, IncP1CC (43)
Fapi-46
Skin Cancer
Jonsson Comprehensive Cancer CenterP1CC (43)
Fluorouracilum
Skin Cancer
Toray Industries, IncP1CC (43)
Imiquimod
Skin Cancer
Toray Industries, IncP1CC (43)
Immunoglobulin G1, Anti-(Human Vascular Endothelial Growth Factor Receptor Type Vegfr-2 Extracellular Domain) (Human Monoclonal Imc-1121B .Gamma.-Chain), Disulphide With Human Monoclonal Imc-1121B .Kappa.-Chain, Dimer
Skin Cancer
Toray Industries, IncP1CC (43)
Irinotecan
Skin Cancer
Toray Industries, IncP1CC (43)
Monoclonal Antibody Trk-950
Skin Cancer
Toray Industries, IncP1CC (43)
5-((R)-SEC-BUTYLAMINO)-N1-((1R,3S,5S)-8-(5-(CYCLOPROPANECARBONYL)PYRIDIN-2-YL)-8-AZABICYCLO(3.2.1)OCTAN-3-YL)-2-METHYLTEREPHTHALAMIDE
Skin Cancer
H. Lee Moffitt Cancer Center and Research InstituteP1CC (41)
Brodalumab
Skin Cancer
Brian Henick, MDP1CC (41)
Cobimetinib
Skin Cancer
H. Lee Moffitt Cancer Center and Research InstituteP1CC (41)
dk210
Skin Cancer
DEKA BiosciencesP1CC (41)
Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer
Skin Cancer
OncoNano Medicine, Inc.P1CC (41)
Onm-501
Skin Cancer
OncoNano Medicine, Inc.P1CC (41)
Vemurafenib
Skin Cancer
H. Lee Moffitt Cancer Center and Research InstituteP1CC (41)
Binimetinib
Skin Cancer
H. Lee Moffitt Cancer Center and Research InstituteEarly P1C (38)
Encorafenib
Skin Cancer
H. Lee Moffitt Cancer Center and Research InstituteEarly P1C (38)